Legend joins the billion-dollar club
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
Rubius confirms the worst
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
First blood: Rubius approaches its big test
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
Bloated on arrival? Biotech's weightiest new issues
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Does amount matter when it comes to a biotech IPO?
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.
After a bumper year, biotech flotations remain on the cards
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
Biotech flotations remain in high demand
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
Another venture funding surge sets up a strong 2018
Cell and gene therapy companies dominate the first quarter, but companies outside these fashionable areas are finding it harder to charm VCs.
2017 rewrites the record books as venture funding accelerates
In terms of venture financing, activity in 2017 outpaced that at the height of the biotech boom in 2015, with 68 biotechs attracted rounds of $50m or more.
